Internal Medicine, Endocrinology, Diabetes, & Metabolism · Bloomfield, CT
NPI
1225004922
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
701 Cottage Grove Rd Ste B220
Bloomfield, CT, 06002
Phone (860) 561-1007
Groups this clinician bills Medicare through
Medicare paid, 2024
$78K
882 services
Medicare patients, 2024
407
Average age 75
Drug cost, 2024
$5.1M
10,048 prescriptions
Company payments, 2025
$18K
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David J Domenichini was code 99214 (office e&m - established), 623 times for 356 patients. In total David J Domenichini billed 882 services in 12 codes, and Medicare paid $78K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-05-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 623 | 356 | $95.05 | $59K |
| 99213 Office E&M - Established | Office | 137 | 110 | $62.79 | $8,603 |
| 95251 Test - Miscellaneous | Office | 33 | 25 | $26.32 | $869 |
| 99215 Office E&M - Established | Office | 30 | 30 | $144.98 | $4,349 |
| 99204 Office E&M - New | Office | 17 | 17 | $121.87 | $2,072 |
| 99203 Office E&M - New | Office | 15 | 15 | $88.79 | $1,332 |
By year: 2022 $89K for 1,020 services; 2023 $82K for 952 services; 2024 $78K for 882 services.
Medicare prescription drug claims, 2024
In 2024, the drug David J Domenichini prescribed most often to Medicare patients was Ozempic (Semaglutide), with 866 prescriptions and refills. In total David J Domenichini wrote 10,048 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 866 | 1,440 | 189 | $1.4M |
| Levothyroxine Sodium Generic | 788 | 2,198 | 212 | $7,878 |
| Synthroid Levothyroxine Sodium | 606 | 1,666 | 163 | $73K |
| Metformin Hcl Generic | 520 | 1,463 | 151 | $3,544 |
| Jardiance Empagliflozin | 383 | 990 | 111 | $588K |
| Atorvastatin Calcium Generic | 307 | 909 | 94 | $2,522 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 304 | 828 | 124 | $34K |
| Tresiba Flextouch U-200 Insulin Degludec | 249 | 614 | 77 | $425K |
| Metformin Hcl Er Metformin Hcl | 243 | 721 | 84 | $2,650 |
| Trulicity Dulaglutide | 238 | 369 | 45 | $368K |
| Tresiba Flextouch U-100 Insulin Degludec | 218 | 537 | 76 | $175K |
| Mounjaro Tirzepatide | 201 | 223 | 39 | $234K |
| Janumet Sitagliptin Phos/Metformin Hcl | 182 | 439 | 57 | $234K |
| Farxiga Dapagliflozin Propanediol | 180 | 453 | 54 | $252K |
| Humalog Kwikpen U-100 Insulin Lispro | 166 | 385 | 63 | $62K |
Brand drugs: 4,849 claims; generic drugs: 4,655 claims; opioid claims: 48.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David J Domenichini $18K ($18K in general payments such as food, travel and fees) from 27 companies. The largest payer was Novo Nordisk Inc with $16K.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 33 | $16K |
| Dexcom, Inc. DXCM | 3 | $177 |
| Amgen Inc. AMGN | 8 | $174 |
| Ascendis Pharma Endocrinology Inc ASND | 4 | $171 |
| Abbott Laboratories ABT | 7 | $157 |
| Mannkind Corporation MNKD | 4 | $129 |
| Lilly USA, LLC LLY | 1 | $121 |
| Antares Pharma, Inc. | 3 | $60.15 |
| Madrigal Pharmaceuticals MDGL | 3 | $54.56 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $47.32 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.